TY  - JOUR
AU  - Reyes, Luis Felipe
AU  - Rodriguez, Alejandro
AU  - Bastidas, Alirio
AU  - Parra-Tanoux, Daniela
AU  - Fuentes, Yuli V
AU  - García-Gallo, Esteban
AU  - Moreno, Gerard
AU  - Ospina-Tascon, Gustavo
AU  - Hernandez, Glenn
AU  - Silva, Edwin
AU  - Díaz, Ana Maria
AU  - Jibaja, Manuel
AU  - Vera, Magdalena
AU  - Díaz, Emilio
AU  - Bodí, María
AU  - Solé-Violán, Jordi
AU  - Ferrer, Ricard
AU  - Albaya-Moreno, Antonio
AU  - Socias, Lorenzo
AU  - Estella, Ángel
AU  - Loza-Vazquez, Ana
AU  - Jorge-García, Ruth
AU  - Sancho, Isabel
AU  - Martin-Loeches, Ignacio
AU  - LIVEN-COVID-19 Investigators and COVID-19 SEMICYUC Study Group
PY  - 2022
DO  - 10.1016/j.jcrc.2022.154014
UR  - http://hdl.handle.net/10668/22297
T2  - Journal of critical care
AB  - Dexamethasone is the only drug that has consistently reduced mortality in patients with COVID-19, especially in patients needing oxygen or invasive mechanical ventilation. However, there is a growing concern about the relation of dexamethasone with...
LA  - en
KW  - COVID-19
KW  - Critical care
KW  - Dexamethasone
KW  - Pneumonia
KW  - Severe COVID-19
KW  - Dexamethasone
KW  - Humans
KW  - Intensive Care Units
KW  - Prospective Studies
KW  - Risk Factors
KW  - SARS-CoV-2
KW  - COVID-19 Drug Treatment
TI  - Dexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19.
TY  - research article
VL  - 69
ER  -